Skip to main content

Table 1 The characteristics of the involved studies

From: Clinical performance of stem cell therapy in patients with acute-on-chronic liver failure: a systematic review and meta-analysis

First authors/published year Country No. Disease etiology Study design Cell source Cell dosage Injection rout Sex (male/female) Age (years) End-point of observation Quality
SCT SMT SCT SMT
Ming Shi/2012 China 43 HBV-ACLF RCT UC-MSCs Each 0.5 × 106/kg, thrice PV 20/4 15/4 40 (24–59) 45 (26–62) 18 months High
Bing-liang Lin/2017 China 110 HBV-ACLF RCT BM-MSCs 1.0 to 10 × 105 cells/kg for 4 weeks PV 53/3 51/3 42.8 ± 8.4 40.0 ± 9.9 24 weeks High
Zheng Zhang/2012 China 45 HBV with decompensated LC Open-labeled, paired, controlled study, CT UC-MSCs Each 0.5 × 106/kg in NS, once every 4 weeks three times PV 14/1 26/4 48 (25–64) 47 (29–64) 12 months Low
Mehdi Mohamadnejad/2013 Iran 25 Decompensated LC (cirrhosis cryptogenic 11, PBC 2, HBV 2, HCV 1, AIH 9) RCT BM-MSCs Median of 195 million (120–295 million) in 100 mL NS PV 7/7 6/5 43.1 ± 17.6 34.6 ± 13.8 12 months Moderate
Liang Peng/2011 China 158 LF caused by HBV Retrospective case control study BM-MSCs In 10 mL of NS HA 50/3 99/6 42.19 ± 10.8 42.22 ± 11.37 48 weeks Very low
Yang-Qiu Bai/2014 China 47 Decompensated LC (43 HBV) Prospective CT BM-MNCs 1.0–11.2 × 1010/L HA 20/12 9/6 46.4 ± 11.6 47.4 ± 11.1 24 months Very low
Laurent Spahr/2013 Switzerland 58 Decompensated ALD (all with cirrhosis, 81% with alcoholic steatohepatitis RCT BM-MNCs 4.7 × 107/kg HA 24/4 20/10 54 (34–66) 56 (37–68) 3 months Moderate
Qinzhi Deng/2015 China 70 HBV-related decompensated cirrhosis Prospective study APBSC 2–4 × 107 HA 20/13 12/23 49.48 ± 11.07 50.20 ± 10.64 48 weeks Low
Mehdi Mohamadnejad/2016 Iran 27 Decompensatedcirrhosis RCT BM-MNCs 20 mL of serum PV 12/6 5/4 43.90 ± 14.84 46.22 ± 15.31 6 months Moderate
Yu-Hua Li/2016 China 45 HBV-ACLF Prospective study UC-MSCs 100 × 106 cells in 60 mL of NS HA 8/3 26/8 51.1 ± 11.2 50.0 ± 10.9 24 months Very low
  1. PBC primary biliary cirrhosis, HBV hepatitis B virus, HCV hepatitis C virus, AIH autoimmune hepatitis, BM-MNCs bone marrow mononuclear cells, HA hepatic artery, MSC mesenchyme stem cell, NA not available, RCT randomized controlled trial, PV peripheral vein